NEJM Interview: Peter Ubel on strategies for protecting patients from high out-of-pocket costs for drugs with questionable benefits.

Peter Ubel discusses the challenges patients face due to high out-of-pocket drug costs. He highlights the complexities of the FDA's drug approval process, particularly around the rushed approvals of drugs with questionable benefits. The conversation delves into the financial implications for patients and advocates for greater regulatory transparency. Additionally, potential policy solutions to regulate drug prices and improve cost-effectiveness for Americans are explored. Ubel emphasizes the need for a balanced approach to ensure both access and affordability.